Search Results

You are looking at 81 - 90 of 309 items for :

Clear All
Full access

Alok A. Khorana

opposed to outpatient thromboprophylaxis, with the exception of IMid-based regimens in patients with myeloma, because it has not been shown to improve survival, because prophylaxis may be expensive and because of concerns regarding extrapolation to larger

Full access

2020 07 12 2020 18 18 12.5 12.5 1767 1767 1769 1769 jnccn20-5037 10.6004/jnccn.2020.5037 Evolving Concepts in the Diagnosis and Staging of Multiple Myeloma Hillengass Jens MD 20 12 2020 07 12 2020 18 18 12.5 12.5 1770 1770 1772 1772 jnccn20-5041 10

Full access

/Refractory Multiple Myeloma Principal Investigator: Michaela Liedtke, MD Condition: Multiple myeloma Institution: Stanford University This is an open-label, phase I, dose-escalation safety study of bortezomib in combination with pralatrexate in patients

Full access

A Phase I Study of Bortezomib (VELCADE) in Combination With Pralatrexate in Relapsed/Refractory Multiple Myeloma Principal Investigator: Michaela Liedtke, MD Condition: Multiple myeloma Institution: Stanford University This is an open

Full access

Constantine S. Mitsiades and Kenneth C. Anderson

marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies . Hematol Oncol Clin North Am 2007 ; 21 : 1007 - 1034 , vii–viii . 5. Jones PA Baylin SB . The fundamental role

Full access

1426 jnccn101419 10.6004/jnccn.2019.5036 Fixed-Duration Versus Until Disease Progression: How Long Should Initial Treatment of Multiple Myeloma Last? Efebera Yvonne A. MD, MPH Shah Nina MD 11 2019 17 17 11.5 11.5 1430 1430 1432 1432 jnccn20195033 10

Full access

Robert W. Carlson

follicular lymphoma. Between these sessions, a second debate evaluated the appropriate length of initial treatment of multiple myeloma. The congress also included 3 interactive sessions featuring patient case studies and panel discussions. In the first

Full access

Severe Hypertriglyceridemia and Acute Pancreatitis Expiration Date: 1/11/14 NCCN Guidelines® Insights: Multiple Myeloma, Version 1.2013 Expiration Date: 1/11/14 Modern Staging of Small Cell Lung Cancer Expiration Date: 1/11/14 CASE REPORT

Full access

11 11 1 1 5 5 9 9 jnccn0110005 10.6004/jnccn.2013.0003 Multiple Myeloma, Version 1.2013 Anderson Kenneth C. 1 MD Alsina Melissa 2 MD Bensinger William 3 MD Biermann J. Sybil 4 MD Cohen Adam D. 5 MD Devine Steven 6

Full access

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology Kumar Shaji K. 1 MD Callander Natalie S. 2 MD Adekola Kehinde 3 MD Anderson Larry 4 MD, PhD Baljevic